A Phase II, Multicenter, Single-Arm Study OF MPDL3280A in Patients with PD-L1−Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Diseases and Conditions Researched
What is the purpose of this trial?
This multicenter, single-arm study will evaluate the efficacy and safety of MPDL 3280A in patients with PD-L1-positive locally advanced or metastatic non-small c ell lung cancer (NSCLC). Patients will receive an intravenous dose of 1200 mg MP DL3280A on Day 1 of 21-day cycles for a maximum of 16 cycles.
Click here for detailed participation information for this trial.
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.